Alaunos Therapeutics appoints Dr. Robert Hofmeister to board, replacing Dr. Christopher Bowden

Alaunos Therapeutics, Inc.

Christopher Bowden resigned from board effective March 30, 2023; no disagreement with company.
Robert Hofmeister appointed as director effective March 30, 2023, filling Bowden's vacancy.
Hofmeister brings over 25 years of T-cell therapy experience; previously CSO at TCR2 Therapeutics.
Hofmeister receives initial option for 150,000 shares and pro-rated annual grant for 16,667 shares.
Hofmeister appointed to Corporate Governance and Nominating and Compensation Committees.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Bowden

Director

TCRT · Alaunos Therapeutics, Inc.

Effective: 2023-03-30
Successor: Robert Hofmeister
Filed: March 30, 2023, 7:59 PM ET

Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.

Appointed

Robert Hofmeister

Director

TCRT · Alaunos Therapeutics, Inc.

Effective: 2023-03-30
Filed: March 30, 2023, 7:59 PM ET

the Board appointed Robert Hofmeister, Ph.D., as a director of the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Bowden resigned as Director at Alaunos Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Hofmeister was appointed as Director at Alaunos Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Robert Hofmeister, Ph.D., as a director of the Company effective immediately.

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-084520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.